The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation

Journal of Molecular Biology

Volumn 425, Issue 3, 2013, Pages 577-593

  Lightwood, Daniel ^a   O'Dowd, Victoria ^a   Carrington, Bruce ^a   Veverka, Vaclav ^b   Carr, Mark D ^b   Tservistas, Markus ^c   Henry, Alistair J ^a   Smith, Bryan ^a   Tyson, Kerry ^a   Lamour, Sabrina ^a   Sarkar, Kaushik ^a   Turner, Alison ^a   Lawson, Alastair D ^a   Bourne, Tim ^a   Gozzard, Neil ^a   Palframan, Roger ^a  

^a UCB PHARMA   (Belgium)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c Pari Pharma GmbH   (Germany)

Author keywords

asthma; Fab; fluorescent foci; inhalation; Keywords; monoclonal antibody

Indexed keywords

CA652.G2 FAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

AEROSOL; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIBODY ENGINEERING; ANTIBODY SCREENING; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CIRCULAR DICHROISM; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DNA SEQUENCE; EPITOPE MAPPING; FIBROBLAST; HEAVY CHAIN; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INHALATION; LIGHT CHAIN; MOLECULAR STABILITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN UNFOLDING; RAT; SEQUENCE ALIGNMENT; TEMPERATURE STRESS; THERMOSTABILITY; TRANSIENT EXPRESSION;

EID: 84872849087     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2012.11.036     Document Type: Article

References (50)

1. M. Wills-Karp Interleukin-13 in asthma pathogenesis Immunol. Rev. 202 2004 175 190
2. G. Grunig, M. Warnock, A.E. Wakil, R. Venkayya, F. Brombacher, and D.M. Rennick Requirement for IL-13 independently of IL-4 in experimental asthma Science 282 1998 2261 2263
3. T.C. van der Pouw Kraan, J.S. van der Zee, L.C. Boeije, E.R. de Groot, S.O. Stapel, and L.A. Aarden The role of IL-13 in IgE synthesis by allergic asthma patients Clin. Exp. Immunol. 111 1998 129 135
4. J.E. Kolodsick, G.B. Toews, C. Jakubzick, C. Hogaboam, T.A. Moore, and A. McKenzie Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts J. Immunol. 172 2004 4068 4076
5. O. Tliba, D. Deshpande, H. Chen, B.C. Van, M. Kannan, R.A. Panettieri Jr.; and Y. Amrani IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle Br. J. Pharmacol. 140 2003 1159 1162
6. D.M. Walter, J.J. McIntire, G. Berry, A.N. McKenzie, D.D. Donaldson, R.H. DeKruyff, and D.T. Umetsu Critical role for IL-13 in the development of allergen-induced airway hyperreactivity J. Immunol. 167 2001 4668 4675
7. M.J. Aman, N. Tayebi, N.I. Obiri, R.K. Puri, W.S. Modi, and W.J. Leonard cDNA cloning and characterization of the human interleukin 13 receptor alpha chain J. Biol. Chem. 271 1996 29265 29270
8. A.L. Andrews, J.W. Holloway, S.M. Puddicombe, S.T. Holgate, and D.E. Davies Kinetic analysis of the interleukin-13 receptor complex J. Biol. Chem. 277 2002 46073 46078
9. A.L. Andrews, T. Nasir, F. Bucchieri, J.W. Holloway, S.T. Holgate, and D.E. Davies IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts J. Allergy Clin. Immunol. 118 2006 858 865
10. K. Arima, K. Sato, G. Tanaka, S. Kanaji, T. Terada, and E. Honjo Characterization of the interaction between interleukin-13 and interleukin-13 receptors J. Biol. Chem. 280 2005 24915 24922
11. S.L. LaPorte, Z.S. Juo, J. Vaclavikova, L.A. Colf, X. Qi, and N.M. Heller Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system Cell 132 2008 259 272
12. B. Miloux, P. Laurent, O. Bonnin, J. Lupker, D. Caput, N. Vita, and P. Ferrara Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex FEBS Lett. 401 1997 163 166
13. D. Caput, P. Laurent, M. Kaghad, J.M. Lelias, S. Lefort, N. Vita, and P. Ferrara Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain J. Biol. Chem. 271 1996 16921 16926
14. S. Fichtner-Feigl, W. Strober, K. Kawakami, R.K. Puri, and A. Kitani IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis Nat. Med. 12 2006 99 106
15. J. Corren, R.F. Lemanske, N.A. Hanania, P.E. Korenblat, M.V. Parsey, and J.R. Arron Lebrikizumab treatment in adults with asthma N. Engl. J. Med. 365 2011 1088 1098
16. L.M. Berry, R. Adams, M. Airey, M.G. Bracher, T. Bourne, and B. Carrington In vitro and in vivo characterisation of anti-murine IL-13 antibodies recognising distinct functional epitopes Int. Immunopharmacol. 9 2009 201 206
17. J. Hacha, K. Tomlinson, L. Maertens, G. Paulissen, N. Rocks, and J.M. Foidart Nebulized anti-IL-13 monoclonal antibody Fab′ fragment reduces allergen-induced asthma Am. J. Respir. Cell Mol. Biol. 47 2012 709 717
18. G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity. 1975 Biotechnology 24 1992 524 526
19. X. Yu, P.A. McGraw, F.S. House, and J.E. Crowe Jr. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies J. Immunol. Methods 336 2008 142 151
20. R.H. Zubler, F. Erard, R.K. Lees, L.M. Van, C. Mingari, L. Moretta, and H.R. MacDonald Mutant EL-4 thymoma cells polyclonally activate murine and human B cells via direct cell interaction J. Immunol. 134 1985 3662 3668
21. L. Wen, M. Hanvanich, C. Werner-Favre, N. Brouwers, L.H. Perrin, and R.H. Zubler Limiting dilution assay for human B cells based on their activation by mutant EL4 thymoma cells: total and antimalaria responder B cell frequencies Eur. J. Immunol. 17 1987 887 892
22. S. Tickle, R. Adams, D. Brown, M. Griffiths, D. Lightwood, and A. Lawson High-throughput screening for high affinity antibodies J. Lab. Autom. 14 2010 303 307
23. P.E. Graves, M. Kabesch, M. Halonen, C.J. Holberg, M. Baldini, and C. Fritzsch A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children J. Allergy Clin. Immunol. 2000 506 513
24. E.A. Kabat, T.T. Wu, H.M. Perry, K.S. Gottesman, and C. Foeller Sequences of proteins of immunological interest, 5th edit 1991 Public Health Service, National Institutes of Health Bethesda, MD
25. J.R. Adair, D.S. Athwal, and J.S. Emtage Humanised Antibodies 1991 International Patent Publication WO91/09967
26. P.J. Lupardus, M.E. Birnbaum, and K.C. Garcia Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2 Structure 18 2010 332 342
27. B.T. Farmer, K.L. Constantine, V. Goldfarb, M.S. Friedrichs, M. Wittekind, and J. Yanchunas Jr Localizing the NADP + binding site on the MurB enzyme by NMR Nat. Struct. Biol. 3 1996 995 997
28. F.W. Muskett, T.A. Frenkiel, J. Feeney, R.B. Freedman, M.D. Carr, and R.A. Williamson High resolution structure of the N-terminal domain of tissue inhibitor of metalloproteinases-2 and characterization of its interaction site with matrix metalloproteinase-3 J. Biol. Chem. 273 1998 21736 21743
29. R.A. Williamson, M.D. Carr, T.A. Frenkiel, J. Feeney, and R.B. Freedman Mapping the binding site for matrix metalloproteinase on the N-terminal domain of the tissue inhibitor of metalloproteinases-2 by NMR chemical shift perturbation Biochemistry 36 1997 13882 13889
30. V. Veverka, T. Crabbe, I. Bird, G. Lennie, F.W. Muskett, R.J. Taylor, and M.D. Carr Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR Oncogene 27 2008 585 595
31. L.C. Waters, V. Veverka, M. Bohm, T. Schmedt, P.T. Choong, and F.W. Muskett Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A Oncogene 26 2007 4941 4950
32. E.Z. Eisenmesser, D.A. Horita, A.S. Altieri, and R.A. Byrd Solution structure of interleukin-13 and insights into receptor engagement J. Mol. Biol. 310 2001 231 241
33. E.Z. Eisenmesser, D.A. Horita, and R.A. Byrd Secondary structure and backbone resonance assignments for human interleukin-13 J. Biomol. NMR 19 2001 93 94
34. F.J. Moy, E. Diblasio, J. Wilhelm, and R. Powers Solution structure of human IL-13 and implication for receptor binding J. Mol. Biol. 310 2001 219 230
35. D.D. Donaldson, M.J. Whitters, L.J. Fitz, T.Y. Neben, H. Finnerty, and S.L. Henderson The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1 J. Immunol. 161 1998 2317 2324
36. N. Feng, S.M. Lugli, B. Schnyder, J.F. Gauchat, P. Graber, and E. Schlagenhauf The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: overexpression of the nonsignaling interleukin-13 receptor alpha2 Lab. Invest. 78 1998 591 602
37. G.K. Hershey IL-13 receptors and signaling pathways: an evolving web J. Allergy Clin. Immunol. 111 2003 677 690
38. A.L. Andrews, I.K. Nordgren, I. Kirby, J.W. Holloway, S.T. Holgate, D.E. Davies, and A. Tavassoli Cytoplasmic tail of IL-13Ralpha2 regulates IL-4 signal transduction Biochem. Soc. Trans. 37 2009 873 876
39. S.O. Rahaman, P. Sharma, P.C. Harbor, M.J. Aman, M.A. Vogelbaum, and S.J. Haque IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells Cancer Res. 62 2002 1103 1109
40. S.O. Rahaman, M.A. Vogelbaum, and S.J. Haque Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2 Cancer Res. 65 2005 2956 2963
41. Z. Zhu, R.J. Homer, Z. Wang, Q. Chen, G.P. Geba, and J. Wang Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production J. Clin. Invest. 103 1999 779 788
42. N. Zimmermann, N.E. King, J. Laporte, M. Yang, A. Mishra, and S.M. Pope Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis J. Clin. Invest. 111 2003 1863 1874
43. J.Q. He, M. Chan-Yeung, A.B. Becker, H. Dimich-Ward, A.C. Ferguson, and J. Manfreda Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children Genes Immun. 4 2003 385 389
44. A. Heinzmann, X.Q. Mao, M. Akaiwa, R.T. Kreomer, P.S. Gao, and K. Ohshima Genetic variants of IL-13 signalling and human asthma and atopy Hum. Mol. Genet. 9 2000 549 559
45. H. Liu, B.S. Jacobs, J. Liu, R.A. Prayson, M.L. Estes, G.H. Barnett, and B.P. Barna Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma Cancer Immunol. Immunother. 49 2000 319 324
46. M. Wang, Z.M. Xing, C. Lu, Y.X. Ma, D.L. Yu, and Z. Yan A common IL-13 Arg130Gln single nucleotide polymorphism among Chinese atopy patients with allergic rhinitis Hum. Genet. 113 2003 387 390
47. S.E. Zitnik, F. Ruschendorf, S. Muller, C. Sengler, Y.A. Lee, and R.W. Griffioen IL13 variants are associated with total serum IgE and early sensitization to food allergens in children with atopic dermatitis Pediatr. Allergy Immunol. 20 2009 551 555
48. F.D. Vladich, S.M. Brazille, D. Stern, M.L. Peck, R. Ghittoni, and D. Vercelli IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation J. Clin. Invest. 115 2005 747 754
49. A.L. Andrews, F. Bucchieri, K. Arima, K. Izuhara, S.T. Holgate, D.E. Davies, and J.W. Holloway Effect of IL-13 receptor alpha2 levels on the biological activity of IL-13 variant R110Q J. Allergy Clin. Immunol. 120 2007 91 97
50. A. Maillet, N. Congy-Jolivet, G.S. Le, L. Vecellio, S. Hamard, and Y. Courty Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization Pharm. Res. 25 2008 1318 1326